What causes insulin resistance is one of the most important and most poorly answered questions in modern metabolic medicine.
Insulin resistance is consistently described as if it has a single cause. Eat too many carbohydrates. Exercise too little. Gain weight. The reality is mechanistically more complex — and clinically more important to understand correctly.
Insulin resistance does not arise from one driver acting alone. It arises from multiple converging biological mechanisms — each operating at the cellular level, each capable of initiating or amplifying the others, and each requiring a distinct understanding if the root cause is to be identified and addressed rather than managed downstream.
This post explains the main biological drivers of insulin resistance at the mechanistic level. Not as a lifestyle checklist — the intervention posts in this cluster cover that ground. This is the biological account: what is actually happening inside cells, in the liver, in adipose tissue, in the gut, and in the body’s circadian signaling systems that produces the state of impaired insulin sensitivity that drives the full downstream trajectory toward metabolic disease.
What you will learn: The cellular mechanisms through which each major driver initiates insulin resistance | Why hyperinsulinemia is itself a driver — not just a consequence | How chronic inflammation impairs insulin receptor signaling at the molecular level | Why the gut-liver axis is the most underestimated pathway in this entire picture | How these drivers interact and amplify each other | What the clinical marker pattern looks like when multiple drivers are operating simultaneously
Clinical Perspective: What I See in Practice
The question I am asked most often in consultation — in one form or another — is: why did this happen to me? The patient has been told they have insulin resistance, or prediabetes, or metabolic syndrome. They want to understand what caused it. And almost universally, what they have been told — if they have been told anything at all — points to one of two things: too much sugar, or too many calories.
Both observations contain partial truth. Neither captures the biology.
What I find consistently when I go through a full consultation is that the root cause picture is almost never singular. The most resistant cases — the ones that are hardest to reverse and that have typically been developing the longest — share a specific combination: established hyperinsulinemia driving further insulin resistance, chronic low-grade inflammation amplifying the signal, and visceral adipose tissue dysfunction creating a self-sustaining FFA spillover loop into the liver. Each of these three drives the others. Once the cycle is established, removing one driver without addressing the others produces incomplete and often temporary improvement.
What surprises patients most in this conversation is not the role of sugar — they have heard about sugar thousands of times. What surprises them is that obesity is the result of a hormonal imbalance, not a caloric failure. They have never heard how differently the pancreas responds to a muffin versus an egg. They do not know that insulin is a profoundly anabolic hormone — that when insulin is high, cells burn glucose and fat remains locked in storage, and that when insulin is low, cells shift to fat oxidation and become insulin sensitive again. They have been managing a hormonal disorder with a caloric framework, and it has not worked, because it was never designed to.
The observation that has shaped my clinical thinking most durably came not from a patient but from two decades of living in Japan and Southeast Asia. I watched populations eat rice three times a day — carbohydrate loads that would horrify most low-carbohydrate advocates — while remaining metabolically healthy across generations. Now type 2 diabetes and metabolic syndrome are rising rapidly across the Far East. The rice did not change. The food environment did. Supermarket culture arrived. Ultra-processed products, industrial seed oils, high-fructose corn syrup, and the full architecture of Western processed food colonized diets that had been metabolically stable for centuries. Microbiome dysbiosis, leaky gut, chronic inflammation, insulin resistance, and autoimmunity followed. That observation is, for me, the clearest possible demonstration that carbohydrate load per se is not the primary villain. The quality of the food environment — and specifically its effect on the gut-liver axis — is the driver that the diet wars have consistently underestimated.
I am firmly in the animal-based protein camp clinically. I recommend keeping carbohydrates around 50 grams per day for patients managing insulin resistance, prioritizing protein from the most bioavailable sources — meat, eggs, fish, dairy — for metabolic rate, insulin sensitivity, nutrient density, and fat-soluble vitamin access. But I hold that position within a framework that recognizes the gut-liver axis as the central mechanistic story — not carbohydrate grams as an isolated variable.
Driver One: Intramyocellular Lipid Accumulation and Skeletal Muscle Insulin Resistance
Skeletal muscle accounts for approximately 80% of insulin-mediated glucose disposal in the postprandial state. It is the primary site at which insulin resistance first becomes established — and the mechanism through which it does so begins not with glucose but with fat.
When fatty acid delivery to skeletal muscle exceeds its oxidative capacity — through chronic energy surplus, physical inactivity, or elevated circulating free fatty acids from insulin-resistant adipose tissue — lipids begin accumulating inside muscle cells. This intramyocellular lipid accumulation is not itself the problem. The problem is what it generates: diacylglycerol (DAG) and ceramides — lipid intermediates that are produced during incomplete fatty acid metabolism and that directly impair insulin signaling.
DAG activates protein kinase C theta (PKCθ) in skeletal muscle — the muscle-specific isoform of the same kinase family that activates PKCε in the liver. PKCθ phosphorylates insulin receptor substrate 1 (IRS-1) at serine residues, impairing its ability to activate the PI3K-Akt signaling cascade that mediates insulin-stimulated GLUT4 translocation to the cell membrane. Without GLUT4 at the membrane, glucose cannot enter the muscle cell efficiently. The pancreas compensates by secreting more insulin — initiating hyperinsulinemia before any glucose marker becomes abnormal.
Ceramides — generated from saturated fatty acids through the sphingolipid synthesis pathway — amplify this impairment through a separate mechanism: they activate protein phosphatase 2A (PP2A) and PKCζ, both of which inhibit Akt directly. Ceramide-mediated Akt inhibition reduces insulin-stimulated glucose uptake, promotes apoptosis in pancreatic beta cells under chronic exposure, and has been identified as an independent predictor of insulin resistance severity in multiple human studies.
The clinical implication is precise: skeletal muscle insulin resistance is not primarily a glucose problem. It is a lipid intermediate problem — driven by the accumulation of DAG and ceramides inside muscle cells that impairs the insulin receptor signaling cascade at the post-receptor level. Reducing the intramyocellular lipid load — through resistance training that increases oxidative capacity, dietary fat quality optimization, and reduction of chronic FFA spillover from adipose tissue — addresses this mechanism at its source.
Driver Two: Hepatic Insulin Resistance and the DAG-PKCε Mechanism
The liver is the second major site of insulin resistance development — and its insulin resistance has consequences that extend far beyond glucose metabolism because the liver is simultaneously the primary regulator of glucose output, triglyceride synthesis, and VLDL export.
The mechanism of hepatic insulin resistance is well-characterized and follows the same DAG-kinase logic as skeletal muscle but involves a different PKC isoform. As free fatty acids delivered to the liver — from adipose tissue lipolysis and dietary sources — accumulate beyond the liver’s oxidative and export capacity, intrahepatic triglycerides and DAG accumulate. DAG activates PKCε in hepatocytes, which translocates to the plasma membrane and directly phosphorylates the insulin receptor at threonine 1160, impairing its kinase activity. Downstream IRS-1 and IRS-2 phosphorylation is reduced, PI3K-Akt signaling is impaired, and the liver loses its ability to suppress gluconeogenesis in response to insulin.
The result — hepatic insulin resistance — means the liver continues producing and releasing glucose into the bloodstream even in the fed, insulin-elevated state. The pancreas responds by secreting additional insulin to overcome this resistance. Fasting insulin climbs. But the liver’s lipogenic response to insulin — mediated through SREBP-1c — remains intact and may even be enhanced. The liver simultaneously produces glucose it should not be producing and fat it should not be producing, driven by the same elevated insulin signal that it is now resistant to for glucose suppression purposes.
This selective hepatic insulin resistance — resistant to glucose suppression, sensitive to lipogenesis — is the metabolic paradox that drives both hyperglycemia and hypertriglyceridemia from the same upstream hormonal disturbance. It is discussed in full mechanistic detail in the post on how insulin resistance drives fatty liver.
Driver Three: Visceral Adipose Tissue Dysfunction and Chronic FFA Spillover
Visceral adipose tissue is not passive storage. In the context of insulin resistance, it becomes a chronically active source of free fatty acid release and pro-inflammatory signal generation that directly drives and sustains insulin resistance in the liver and skeletal muscle.
In healthy adipose tissue, insulin suppresses lipolysis by inhibiting hormone-sensitive lipase (HSL). In insulin-resistant adipose tissue, this suppression fails — HSL remains active and continues releasing fatty acids into the portal and systemic circulation around the clock, regardless of the fed or fasted state.
The portal FFA load delivered to the liver from visceral adipose tissue is the primary substrate driver of hepatic fat accumulation — accounting for approximately 60% of hepatic triglyceride in individuals with established fatty liver, as documented in the landmark Donnelly tracer study. As hepatic fat accumulates, DAG-PKCε-mediated hepatic insulin resistance follows. As hepatic insulin resistance worsens, compensatory hyperinsulinemia deepens — which further promotes visceral fat deposition through insulin’s lipogenic signaling in visceral adipocytes. The cycle is established and self-reinforcing.
Simultaneously, visceral adipocytes and their resident macrophages secrete pro-inflammatory adipokines — TNF-alpha, IL-6, resistin — that directly impair IRS-1 signaling through serine phosphorylation in both liver and skeletal muscle. Adiponectin — the anti-inflammatory, AMPK-activating adipokine — is progressively suppressed as visceral fat expands, removing the primary endogenous insulin-sensitizing signal at exactly the moment it is most needed.
The full bidirectional mechanism between visceral fat and insulin resistance is covered in detail in the post on insulin resistance and visceral fat.
Driver Four: Chronic Low-Grade Inflammation and the NF-κB Pathway
Chronic systemic inflammation is both a consequence and a driver of insulin resistance — and its role as an independent upstream initiator is consistently underappreciated in both conventional and functional medicine contexts.
The central molecular mechanism is well-defined. Pro-inflammatory cytokines — particularly TNF-alpha and IL-6 from multiple sources including visceral adipose tissue, activated macrophages, and gut-derived LPS exposure — activate the NF-κB transcription factor and the JNK (c-Jun N-terminal kinase) pathway. JNK directly phosphorylates IRS-1 at serine 307, converting IRS-1 from an activator to an inhibitor of insulin receptor signaling. This is the same serine phosphorylation that DAG-activated PKC isoforms produce — inflammation and lipid accumulation converge on the same molecular switch.
The clinical significance of this convergence is that inflammation alone — independent of dietary carbohydrate or caloric surplus — is sufficient to initiate and sustain insulin resistance. A person with a gut-derived LPS translocation problem, a chronic sleep deprivation-induced inflammatory state, or a visceral adiposity-driven cytokine environment will develop impaired IRS-1 signaling regardless of their macronutrient ratios.
IκB kinase beta (IKKβ) — the kinase that activates NF-κB — also directly phosphorylates IRS-1 at serine residues, providing a second parallel pathway through which inflammatory signaling impairs insulin action. Salicylates — which inhibit IKKβ — have been demonstrated to improve insulin sensitivity in insulin-resistant individuals, providing direct mechanistic confirmation of inflammation’s causal role independent of other variables.
HsCRP — high sensitivity C-reactive protein — is the accessible clinical proxy for this inflammatory driver. In patients where hsCRP is elevated above 1.0 mg/L in the absence of acute infection, chronic low-grade inflammation is a significant contributor to the insulin resistance picture and must be addressed alongside dietary and metabolic interventions.
Driver Five: Gut Dysbiosis, Intestinal Permeability, and the LPS-TLR4 Pathway
The gut-liver axis is, in my clinical experience, the most consistently underestimated driver of insulin resistance — both in conventional medicine, where it is virtually absent from the diagnostic framework, and in much of the functional medicine world, where it is discussed but rarely placed at the center of the mechanistic account.
The intestinal barrier functions as a selective interface between the gut microbiome and the portal circulation. Tight junction proteins between enterocytes — including occludin, claudins, and zonula occludens proteins — prevent bacterial components from crossing into the bloodstream. When this barrier is disrupted — by ultra-processed food components, industrial seed oils, emulsifiers, HFCS, chronic psychological stress, sleep deprivation, or antibiotic exposure — its selectivity is compromised.
Lipopolysaccharide (LPS) — a component of the outer membrane of gram-negative bacteria — translocates across the compromised intestinal barrier and enters the portal vein. The liver receives this LPS load first. Kupffer cells — the liver’s resident macrophages — express TLR4 receptors that bind LPS and activate NF-κB through MyD88-dependent signaling. The downstream inflammatory cascade produces hepatic TNF-alpha and IL-6, directly impairing hepatic insulin receptor signaling through the IRS-1 serine phosphorylation mechanism described above.
This process — metabolic endotoxemia — was characterized in Cani et al.’s landmark 2007 study, which demonstrated that subclinical LPS elevation was sufficient to initiate obesity and insulin resistance in mice independently of caloric intake. Subsequent human studies have confirmed that circulating LPS is elevated in individuals with type 2 diabetes, metabolic syndrome, and non-alcoholic fatty liver disease — and that dietary patterns high in ultra-processed foods produce measurable increases in circulating LPS within days.
The clinical relevance for patients consuming ultra-processed foods — including the sports nutrition products discussed in the previous post — is direct and mechanistically precise. These products disrupt the intestinal barrier, elevate circulating LPS, activate hepatic TLR4 signaling, and produce hepatic insulin resistance through the inflammatory pathway. This occurs independently of their macronutrient content and independently of caloric surplus. The gut-liver axis is not a secondary consideration in the insulin resistance story. For many patients — particularly those whose diet appears reasonable by conventional standards but contains chronic ultra-processed food exposure — it is the primary mechanism.
Driver Six: Circadian Disruption and the Cortisol-Insulin Axis
Insulin sensitivity follows a pronounced circadian rhythm. It peaks in the morning — when cortisol is naturally elevated as part of the cortisol awakening response, paradoxically priming cellular glucose uptake for the day ahead — and declines progressively through the afternoon and evening. The same meal consumed at 8am produces a substantially smaller insulin response and more efficient glucose clearance than the same meal consumed at 8pm. This is not a minor variation. It is a fundamental feature of human metabolic biology.
Circadian disruption — through irregular sleep timing, chronic sleep deprivation, shift work, late-night eating, and artificial light exposure suppressing melatonin — directly impairs this rhythm through multiple mechanisms.
Cortisol dysregulation is the primary pathway. In a healthy circadian cycle, cortisol rises sharply upon waking, drives the morning insulin sensitivity window, and declines through the day. In chronic sleep deprivation and circadian disruption, the cortisol awakening response is blunted, daytime cortisol remains chronically elevated at low levels, and the normal evening decline is attenuated. Chronically elevated cortisol drives hepatic gluconeogenesis through glucocorticoid receptor activation — the liver produces glucose autonomously — and reduces peripheral insulin sensitivity through suppression of GLUT4 expression in skeletal muscle.
CLOCK gene disruption — the molecular mechanism through which circadian rhythm regulates metabolic function — directly impairs pancreatic beta cell function, reduces GLUT4 expression in peripheral tissues, and alters adipose tissue lipolytic patterns in ways that increase FFA spillover independent of dietary composition. Shift workers have measurably higher rates of insulin resistance and type 2 diabetes than matched controls, providing population-level confirmation of the circadian mechanism’s clinical significance.
Late-night eating compounds this through a specific and underappreciated mechanism: evening meals consumed when insulin sensitivity is at its circadian nadir produce larger postprandial insulin responses, longer-duration glucose elevations, and greater hepatic lipogenic stimulus than identical meals consumed earlier — driving both hyperinsulinemia and hepatic fat accumulation through a timing pathway that is entirely independent of macronutrient or caloric content.
Driver Seven: Hyperinsulinemia as an Independent Driver
The final driver is the one most consistently absent from discussions of insulin resistance causation — because it is typically listed only as a consequence. Hyperinsulinemia is both.
Chronic overexposure to insulin drives downregulation of insulin receptors across all insulin-sensitive tissues. This is a fundamental regulatory mechanism — cells reduce receptor expression in response to chronic ligand excess to prevent overstimulation. The result is that the hyperinsulinemia produced by compensatory pancreatic secretion in response to developing insulin resistance directly deepens that resistance by reducing the receptor density available for insulin signaling.
This self-reinforcing loop — insulin resistance drives hyperinsulinemia, hyperinsulinemia deepens insulin resistance — is the central amplification mechanism that turns an initially addressable metabolic state into an established and progressive one. It is why early detection through fasting insulin measurement is so clinically important: identifying and interrupting this loop at Stage 2 — before glucose becomes abnormal — is incomparably more effective than addressing it after years of self-reinforcing progression.
Hyperinsulinemia also drives visceral fat deposition independently — through its lipogenic signaling in visceral adipocytes — creating a third amplification loop alongside the inflammatory and lipid intermediate pathways. The three loops operate simultaneously and reinforce each other, which is why the most severe and treatment-resistant insulin resistance cases share the combination of established hyperinsulinemia, chronic low-grade inflammation, and visceral adipose tissue dysfunction operating in parallel.
What Causes Insulin Resistance: How All Seven Drivers Converge Into One Loop
No driver operates in isolation. In clinical practice the most important insight is not which single driver is present — it is how many are operating simultaneously and how far the self-reinforcing cycles have progressed.
The convergence pattern that produces the most severe and most resistant insulin resistance follows a consistent architecture:
Ultra-processed food exposure disrupts the gut microbiome and intestinal barrier → LPS enters portal circulation → hepatic TLR4 activation → NF-κB inflammatory cascade → IRS-1 serine phosphorylation → hepatic insulin resistance → compensatory hyperinsulinemia → visceral fat deposition → portal FFA spillover → DAG-PKCε hepatic insulin resistance → deeper hyperinsulinemia → receptor downregulation → skeletal muscle DAG-PKCθ and ceramide accumulation → peripheral insulin resistance → circadian disruption amplifying cortisol → gluconeogenesis and GLUT4 suppression → further hyperinsulinemia.
Each arrow in that sequence represents a clinically addressable intervention point. The earlier the intervention — and the more drivers it addresses simultaneously — the more complete and durable the reversal.
The marker panel that reflects this convergence in practice is the same one used throughout this cluster: fasting insulin, HOMA-IR, triglyceride-to-HDL ratio, ALT and GGT, hsCRP, homocysteine, waist circumference, and waist-to-height ratio. Together they provide a clinical picture of how many drivers are active and how far the downstream consequences have progressed — information that no single marker and no standard screening panel captures alone.
A Note on Uncertainty
The mechanisms described in this post are among the best-characterized pathways in metabolic research. The DAG-PKC mechanism in muscle and liver, the LPS-TLR4-NF-κB pathway, ceramide-mediated Akt inhibition, and circadian CLOCK gene effects on insulin sensitivity are all validated across multiple human studies and mechanistic research programs.
What remains more variable is the relative contribution of each driver in any given individual. The gut-liver axis dominates in some patients. Intramyocellular lipid accumulation dominates in others. Circadian disruption is the primary amplifier in a third group. Clinical assessment — integrating the full marker panel with dietary history, sleep patterns, stress context, and physical examination — is required to identify which drivers are most active and to prioritize intervention accordingly.
Next Steps
If you are experiencing the downstream consequences of insulin resistance — fatigue, central fat accumulation, dyslipidemia, hormonal disruption, or cognitive decline — and have been told that your standard labs are normal, the appropriate next step is a metabolic assessment that measures the markers that actually reflect the upstream biological drivers described in this post.
Fasting insulin. HOMA-IR. Triglyceride-to-HDL ratio. hsCRP. Liver enzymes. Waist circumference. These are the instruments that read the biological drivers. Standard glucose and HbA1c are the instruments that read the downstream consequences — after a decade of silent progression.
Insulin resistance does not begin with abnormal glucose. It begins with the biological drivers described in this post — operating silently, measurably, and addressably — years before any standard screening test flags anything at all.
People Also Ask
What is the root cause of insulin resistance?
Insulin resistance does not have a single root cause. It develops through multiple converging biological mechanisms — intramyocellular lipid accumulation impairing muscle insulin signaling, hepatic fat accumulation activating the DAG-PKCε pathway, visceral adipose tissue releasing chronic FFA into portal circulation, gut-derived LPS triggering hepatic TLR4 inflammation, circadian disruption impairing cortisol rhythm and GLUT4 expression, and hyperinsulinemia itself downregulating insulin receptors. In most patients, multiple drivers operate simultaneously and reinforce each other.
Does inflammation cause insulin resistance?
Yes — directly and through well-characterized molecular mechanisms. Pro-inflammatory cytokines including TNF-alpha and IL-6 activate JNK and IKKβ, which phosphorylate IRS-1 at serine residues and convert it from an activator to an inhibitor of insulin receptor signaling. Chronic low-grade inflammation from visceral adipose tissue, gut-derived LPS, or sleep deprivation is sufficient to initiate and sustain insulin resistance independently of dietary carbohydrate or caloric surplus.
Can gut dysbiosis cause insulin resistance?
Yes. Disruption of the intestinal barrier allows LPS from gram-negative bacteria to enter the portal circulation — a state called metabolic endotoxemia. LPS activates TLR4 receptors on hepatic Kupffer cells, triggering NF-κB-mediated inflammation that directly impairs hepatic insulin signaling. This pathway operates independently of macronutrient content and has been demonstrated in human studies to be elevated in individuals with type 2 diabetes and metabolic syndrome.
What role does cortisol play in insulin resistance?
Cortisol is counter-regulatory to insulin. Chronically elevated cortisol — from sleep deprivation, psychological stress, or circadian disruption — drives hepatic gluconeogenesis through glucocorticoid receptor activation and suppresses GLUT4 expression in skeletal muscle, reducing insulin-mediated glucose uptake. Late-night eating amplifies this by coinciding elevated cortisol with the circadian nadir of insulin sensitivity, producing disproportionately large postprandial insulin responses from the same meal that would be handled efficiently earlier in the day.
Is insulin resistance caused by eating too many carbohydrates?
Carbohydrate load is one driver among several — not the sole cause. High refined carbohydrate and sugar intake drives chronic insulin secretion that progressively reduces receptor sensitivity. But gut-derived inflammation from ultra-processed food components, intramyocellular lipid accumulation from chronic energy surplus and inactivity, visceral adipose FFA spillover, and circadian disruption all cause insulin resistance through mechanisms entirely independent of carbohydrate intake. The food environment — specifically ultra-processed food quality — appears to be a more precise driver than carbohydrate quantity alone.
What is the first sign that insulin resistance is developing?
The earliest detectable signal is compensatory hyperinsulinemia — elevated fasting insulin in the context of still-normal fasting glucose and HbA1c. This reflects the pancreas secreting excess insulin to maintain glucose control in the face of developing cellular insulin resistance. Fasting insulin above 10 µIU/mL, a rising triglyceride-to-HDL ratio, and increasing waist circumference are the three earliest accessible clinical signals — appearing years before any glucose-based marker becomes abnormal.
About the Author
Morteza Ariana is a State-Certified Functional Nutritionist based in Germany, specializing in insulin resistance, type 2 diabetes, and root-cause metabolic restoration. He holds advanced training in systems-based physiology and has worked with patients across the U.S. and Europe for over 10 years.
His clinical framework is built around a core principle that mainstream medicine consistently overlooks: chronically elevated insulin — not blood glucose — is the earliest and most actionable driver of metabolic disease. That conviction was shaped in part by his own experience with hyperinsulinemia in 2016, and deepened through a decade of clinical practice and the study of leading researchers in metabolic medicine including Benjamin Bikman, Joseph Kraft, Gerald Reaven, Jason Fung, and Stephen Phinney.
His work focuses on identifying and correcting the upstream metabolic signals — insulin load, liver-gut axis dysfunction, circadian misalignment, and micronutrient gaps — that standard screening misses entirely. Patient outcomes are documented, anonymized, and published on this site.
If this resonates, the next step is clarity
The Metabolic Restoration Blueprint is a structured 12-week framework designed to correct upstream metabolic drivers — not just manage symptoms.
Key References
- Samuel VT, Shulman GI. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. Journal of Clinical Investigation. 2016;126(1):12–22.
- Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiological Reviews. 2018;98(4):2133–2223.
- Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867.
- Cani PD, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–1772.
- Bikman BT, Summers SA. Ceramides as modulators of cellular and whole-body metabolism. Journal of Clinical Investigation. 2011;121(11):4222–4230.
- Eckel-Mahan K, Sassone-Corsi P. Metabolism and the circadian clock converge. Physiological Reviews. 2013;93(1):107–135.
- Jornayvaz FR, Shulman GI. Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. Cell Metabolism. 2012;15(5):574–584.
- Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607.
- Sutton EF, et al. Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. Cell Metabolism. 2018;27(6):1212–1221.
- Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine Reviews. 2000;21(6):697–738.